LPL and small cell lung carcinoma: On the other hand, the LPL agonist decreased the risk of SCLC via ApoB (OR 0.20, 95% CI 0.07–0.58, p = 0.012) and TG (OR 0.58, 95% CI 0.43–0.77, p = 0.003) reduction by 1 SD.